These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 31556765)

  • 1. Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.
    Yilmaz A; Mellgren Å; Fuchs D; Nilsson S; Blennow K; Zetterberg H; Gisslén M
    Infect Dis (Lond); 2019; 51(11-12):838-846. PubMed ID: 31556765
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
    Campo R; DeJesus E; Bredeek UF; Henry K; Khanlou H; Logue K; Brinson C; Benson P; Dau L; Wang H; White K; Flaherty J; Fralich T; Guyer B; Piontkowsky D
    Clin Infect Dis; 2013 Jun; 56(11):1637-45. PubMed ID: 23362296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
    Bosch B; Akpomiemie G; Chandiwana N; Sokhela S; Hill A; McCann K; Qavi A; Mirchandani M; Venter WDF
    Clin Infect Dis; 2023 Apr; 76(8):1492-1495. PubMed ID: 36519389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A; Chastek B; Gruber J; Majethia S; Zachry W; Mezzio D; Rock M; Anderson A; Cohen JP
    J Manag Care Spec Pharm; 2024 Aug; 30(8):817-824. PubMed ID: 39088337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.
    Del Amo J; Polo R; Moreno S; Martínez E; Cabello A; Iribarren JA; Curran A; Macías J; Montero M; Dueñas C; Mariño AI; de la Cámara SP; Díaz A; Arribas JR; Jarrín I; Hernán MA;
    AIDS; 2022 Dec; 36(15):2171-2179. PubMed ID: 36382436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
    Guillemi SA; Ling SH; Dahlby JS; Yip B; Zhang W; Hull MW; Lima VD; Hogg RS; Werb R; Montaner JS; Harris M
    J Int AIDS Soc; 2016; 19(1):20995. PubMed ID: 27624144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
    BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
    Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial.
    Wang R; Sun L; Wang X; Zhai Y; Wang L; Ma P; Wu C; Zhou Y; Chen R; Wang R; Zhang F; Hua W; Li A; Xia W; Gao Y; Li R; Lv S; Shao Y; Cao Y; Zhang T; Wu H; Cai C; Dai L
    Clin Infect Dis; 2024 Jul; 79(1):169-176. PubMed ID: 38236137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
    Hermansson L; Yilmaz A; Price RW; Nilsson S; McCallister S; Makadzange T; Das M; Zetterberg H; Blennow K; Gisslen M
    PLoS One; 2019; 14(12):e0226276. PubMed ID: 31826005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.
    Arae H; Tateyama M; Nakamura H; Tasato D; Kami K; Miyagi K; Maeda S; Uehara H; Moromi M; Nakamura K; Fujita J
    Intern Med; 2016; 55(23):3435-3440. PubMed ID: 27904105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.
    Mu Y; Pham M; Podany AT; Cory TJ
    Expert Opin Pharmacother; 2020 Mar; 21(4):389-397. PubMed ID: 31957507
    [No Abstract]   [Full Text] [Related]  

  • 18. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
    Devred I; Kayembe K; Valin N; Rougier H; Shinga BW; Lambert-Niclot S; Chiarabini T; Meyohas MC; Lacombe K
    BMC Infect Dis; 2023 Sep; 23(1):578. PubMed ID: 37667182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.